Somaxon Pharmaceuticals, Inc. (Somaxon) is a publicly held research focused specialty pharmaceutical company. It is engaged in research and development of innovative therapeutics for several central nervous system related disorders. The company currently develops treatments for sleeping disorders like insomnia. It develops silenor, an oral tablet formulation of doxepin as its lead product candidate is for the treatment of insomnia.
The product is approved by the US Food and Drug Administration (FDA) which is used to treat insomnia. Somaxon conducts market research and accordingly develop the drug. The operational presence of the company includes Europe, Canada, Japan and Australia.
Somaxon Pharmaceuticals, Inc. Key Recent Developments. . .
Apr 12, 2010: Somaxon Names Tran Nguyen As Vice President, CFO And Announces Senior Leadership Promotions
Mar 19, 2010: Somaxon Pharma´s Insomnia Drug Gets FDA Approval
May 11, 2010: Somaxon Reports Net Loss Of $4.2 Million For Q1 2010
This comprehensive SWOT profile of Somaxon Pharmaceuticals, Inc. provides you an in-depth strategic analysis of the company´s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company´s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
This company report forms part of our ´Profile on Demand´ service, covering over 50,000 of the world´s leading companies. Once purchased, our highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Somaxon Pharmaceuticals, Inc. including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).
Subscribe to:
Post Comments (Atom)
Superhit News
-
US health regulator USFDA has issued a warning letter to German drug firm Fresenius Kabi AG for lapses at its drug manufacturing fac... -
Goods and Service Tax (GST) is high on the agenda for the new government and its rollout is a priority. GST will benefit the Indian pharma... -
Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license ...
-
Physiomics: Reports difficult trading but highlights growing interest from big pharmaceutical groupsPhysiomics ( LON:PYC ) said that trading conditions were difficult in the six months ended 31 December 2010, but it believes it is in a be...
-
Hindusthan National Glass and Industries Ltd is expected to finalize a strategic overseas acquisition in the pharmaceuticals space in the n...
-
The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about th... -
The government is hoping to see the implementation of the track and trace system for domestic and export supply chain in another one y... -
India's Central Drugs Standard Control Organization (CDSCO) has suspended the manufacturing of eye drops at the Chennai-based firm after... -
Diclofenac injection is a painkiller which is manufactured by Themis Medicare Ltd and marketed by Novartis India under the brand name ... -
Amylin Pharmaceuticals, Inc. AMLN +16.15% and Alkermes plc ALKS +4.61% today announced that the U.S. Food and Drug Administration (FDA) has ...
No comments:
Post a Comment